[(18)F]Fluciclatide PET as a biomarker of response to combination therapy of pazopanib and paclitaxel in platinum-resistant/refractory ovarian cancer

BACKGROUND: Angiogenesis is a driver of platinum resistance in ovarian cancer. We assessed the effect of combination pazopanib and paclitaxel followed by maintenance pazopanib in patients with platinum-resistant/refractory ovarian cancer. Integrins α(v)β(3) and α(v)β(5) are both upregulated in tumor...

Full description

Saved in:
Bibliographic Details
Published in:Eur J Nucl Med Mol Imaging
Main Authors: Sharma, Rohini, Valls, Pablo Oriol, Inglese, Marianna, Dubash, Suraiya, Chen, Michelle, Gabra, Hani, Montes, Ana, Challapalli, Amarnath, Arshad, Mubarik, Tharakan, George, Chambers, Ed, Cole, Tom, Lozano-Kuehne, Jingky P., Barwick, Tara D., Aboagye, Eric O.
Format: Artigo
Language:Inglês
Published: Springer Berlin Heidelberg 2019
Subjects:
Original Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC7101300/
https://ncbi.nlm.nih.gov/pubmed/31754793
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00259-019-04532-z
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items